45.00
+0.56(+1.26%)
Currency In USD
| Previous Close | 44.44 |
| Open | 44.48 |
| Day High | 45.58 |
| Day Low | 44.22 |
| 52-Week High | 57.65 |
| 52-Week Low | 29.16 |
| Volume | 597,377 |
| Average Volume | 838,189 |
| Market Cap | 2.52B |
| PE | -128.57 |
| EPS | -0.35 |
| Moving Average 50 Days | 48.59 |
| Moving Average 200 Days | 38.06 |
| Change | 0.56 |
If you invested $1000 in Supernus Pharmaceuticals, Inc. (SUPN) 10 years ago, it would be worth $2,793.3 as of November 15, 2025 at a share price of $45. Whereas If you bought $1000 worth of Supernus Pharmaceuticals, Inc. (SUPN) shares 5 years ago, it would be worth $2,012.52 as of November 15, 2025 at a share price of $45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
GlobeNewswire Inc.
Nov 12, 2025 9:05 PM GMT
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced to
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
GlobeNewswire Inc.
Oct 21, 2025 9:00 PM GMT
ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announ
Supernus Pharmaceuticals to Participate in September Investor Conferences
GlobeNewswire Inc.
Aug 27, 2025 8:15 PM GMT
ROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced to